Nureca Limited has filed a disclosure under Regulation 10(6) of SEBI Takeover Regulations dated January 27, 2026, reporting an increase in promoter group shareholding following the completion of its share buyback program. The company's promoter group shareholding has risen from 64.97% to 68.09% due to the extinguishment of shares purchased during the buyback.

Share Buyback Impact on Ownership Structure

The change in shareholding percentage resulted from the company's share buyback program that opened on December 18, 2025, and closed on December 24, 2025. The shares were subsequently extinguished on January 07, 2026. Importantly, the promoter group did not acquire any additional shares during this process - their percentage increase stems from the reduction in total share capital following the buyback.

Promoter Group Composition and Holdings

The promoter group consists of five entities, with Saurabh Goyal holding the largest stake. The individual shareholding details show how each member's percentage increased proportionally due to the reduced share capital.

Regulatory Compliance and Exemptions

The disclosure was made under Regulation 10(6) of the SEBI Takeover Regulations, with the promoter group claiming exemption under Regulation 10(4)(c). This exemption applies when the increase in shareholding percentage results from a buyback rather than fresh acquisition of shares. The company confirmed that no prior intimation under Regulation 10(5) was required as the transaction qualified for the specified exemption.

Corporate Structure Details

Nureca Limited is listed on both BSE Limited (scrip code: 532649) and National Stock Exchange of India Limited (scrip: NECLIFE). The disclosure was signed by all promoter group members on January 27, 2026, from Chandigarh, with Saurabh Goyal also signing on behalf of Nectar Biopharma Private Limited in his capacity as Director (DIN: 00136037).

Nureca Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, showcasing strong operational performance and a return to profitability. The home healthcare and wellness brand demonstrated significant growth across key financial metrics during the reporting period.

Strong Revenue Growth in Q3FY26

The company's financial performance for Q3FY26 reflected robust business momentum with substantial year-on-year improvements:

The company's total income from operations surged to ₹396.40 crores in Q3FY26, representing a remarkable 45.7% increase compared to ₹272.08 crores in the corresponding quarter of the previous fiscal year.

Profitability Turnaround

Nureca achieved a significant milestone by returning to profitability during the quarter. The company reported a net profit after tax of ₹32.31 crores in Q3FY26, marking a complete turnaround from the net loss of ₹32.89 crores recorded in Q3FY25. This positive shift demonstrates the effectiveness of the company's operational strategies and market positioning.

Nine-Month Performance Overview

The nine-month period ended December 31, 2025, showed sustained growth momentum across the business:

For the nine-month period, total income from operations reached ₹1,118.05 crores, while net profit after tax stood at ₹69.22 crores, indicating consistent performance throughout the fiscal year.

Consolidated vs Standalone Performance

Both standalone and consolidated results showed similar positive trends, with consolidated total income from operations at ₹396.42 crores for Q3FY26 compared to ₹264.63 crores in Q3FY25. The consolidated net profit after tax reached ₹37.34 crores in Q3FY26, against a loss of ₹28.01 crores in the previous year's corresponding quarter.

Earnings Per Share Improvement

The company's earnings per share showed significant improvement, with basic and diluted EPS reaching ₹3.39 for Q3FY26 compared to a loss per share of ₹3.29 in Q3FY25. For the nine-month period, EPS stood at ₹7.25, reflecting the company's enhanced profitability and value creation for shareholders.

The Board of Directors confirmed that the limited review reports do not contain any modified opinion, and the detailed financial results are available on the company's website and stock exchange platforms for comprehensive review by stakeholders.